Literature DB >> 11125226

Penetration of minocycline hydrochloride into lung tissue and sputum.

A Watanabe1, Y Anzai, K Niitsuma, M Saito, K Yanase, M Nakamura.   

Abstract

Penetration of minocycline hydrochloride (MINO) into lung tissue and sputum was investigated. MINO (100 mg) was intravenously infused over 30 min to 14 patients before lung surgery: the concentration of MINO was determined in 16 lung tissue samples which were collected between 0.25 and 5.0 h after infusion. The mean concentration of MINO in lung tissue sample was 2.92 +/- 1.43 microg/g, and the mean lung tissue/plasma ratio of MINO concentration was 3.71 +/- 2.36. MINO was infused intravenously over 60 min twice daily to 5 patients with a chronic respiratory disease for 3-7 days. The concentration of MINO in sputum and in serum was determined on day 3. The mean maximum concentration of MINO in sputum sample was 2.12 +/- 2.20 microg/g, and the mean sputum/serum ratio of MINO concentration was 0.56 +/- 0.47. The concentration of MINO in sputum showed little time-related variation and remained as high as 0.74 microg/g until 10 h after infusion. The concentration of MINO in sputum and in serum after intravenous drip infusion was about twice as high as that after oral administration at the same dose. The breakpoint was 1.88 for MINO, as calculated by the formula established by the Japan Society of Chemotherapy. Copyright 1999 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11125226     DOI: 10.1159/000048494

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  3 in total

1.  Pharmacokinetics and Pharmacodynamics of Minocycline against Acinetobacter baumannii in a Neutropenic Murine Pneumonia Model.

Authors:  Jian Zhou; Kimberly R Ledesma; Kai-Tai Chang; Henrietta Abodakpi; Song Gao; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

2.  Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multicenter Study (ACUMIN).

Authors:  Thomas P Lodise; Scott Van Wart; Zoe M Sund; Adam M Bressler; Akram Khan; Amy T Makley; Yasir Hamad; Robert A Salata; Fernanda P Silveira; Matthew D Sims; Badih A Kabchi; Mohamed A Saad; Carrie Brown; Randolph E Oler; Vance Fowler; Richard G Wunderink
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

Review 3.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis.

Authors:  Andrew Burke; Daniel Smith; Chris Coulter; Scott C Bell; Rachel Thomson; Jason A Roberts
Journal:  Clin Pharmacokinet       Date:  2021-05-13       Impact factor: 5.577

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.